I Need Cancer Care
Research & Clinical Trials
Innovative Clinical Research
Memorial Cancer Institute conducts leading edge research, offering innovative treatment options. We collaborate with several highly regarded and established programs, as well as with pharmaceutical companies, to bring you a wide range of groundbreaking clinical trials.
These affiliations include:
We currently offer our patients access to National Cancer Institute (NCI)- sponsored clinical trials, as well as pharmaceutical and industry-sponsored research. Through our participation in clinical trials, Memorial Cancer Institute has contributed to the development and approval of several important cancer drugs, such as Herceptin, Tykerb, Avastin and Zometa, among others.
Leading-Edge Cancer Care
As part of our comprehensive cancer program, our patients have the opportunity to participate in unique research studies tailored to their care, which may not be available to them at other cancer centers. Our research program includes a full range of clinical trials in lung cancer, breast cancer, leukemia/lymphoma/multiple myeloma and gastrointestinal cancer.
In addition, we offer access to clinical studies designed for patients with rare cancers that are more challenging to treat, such as sarcoma, brain cancer and melanoma. In many cases, Memorial Cancer Institute is the only place in South Florida where you can receive the most promising treatments in cancer available today. Visit our cancer-specific sections for details, and talk to your cancer care team about clinical research and clinical trials that may be right for you.
See our complete, updated listing of open clinical trials.
Memorial Cancer Institute, in cooperation with EmergingMed, also offers a free Clinical Trials Matching and Referral Service. This service provides unlimited access to current, verified clinical trial information. Click here or call 866-890-6618 to learn about current trials available to you.
Please call Memorial Cancer Institute to schedule an appointment: 954-265-4325, or email us.